Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 1,253

Reinvent Yourself: The Playboy Interview with Ray Kurzweil

Many think author, inventor and data scientist Ray Kurzweil is a prophet for our digital age. A few say he’s completely nuts. Kurzweil, who heads a team of more than 40 as a director of engineering at Google, believes advances in technology and medicine are pushing us toward what he calls the Singularity, a period of profound cultural and evolutionary change in which computers will outthink the brain and allow people—you, me, the guy with the man-bun ahead of you at Starbucks—to live forever. He dates this development at 2045.

Raymond Kurzweil was born February 12, 1948, and he still carries the plain, nasal inflection of his native Queens, New York. His Jewish parents escaped Hitler’s Austria, but Kurzweil grew up attending a Unitarian church. He worshipped knowledge above all, and computers in particular. His grandmother was one of the first women in Europe to earn a Ph.D. in chemistry. His uncle, who worked at Bell Labs, taught Ray computer science in the 1950s, and by the age of 15, Kurzweil was designing programs to help do homework. Two years later, he wrote code to analyze and create music in the style of various famous composers. The program won him the prestigious Westinghouse Science Talent Search, a prize that got the 17-year-old an invitation to the White House. That year, on the game show I’ve Got a Secret, Kurzweil pressed some buttons on a data processor the size of a small car. It coughed out original sheet music that could have been written by Brahms.

After earning degrees in computer science and creative writing at MIT, he began to sell his inventions, including the first optical character recognition system that could read text in any normal font. Kurzweil knew a “reading machine” could help the blind, but to make it work, he first had to invent a text-to-speech synthesizer, as well as a flatbed scanner; both are still in wide use. In the 1980s Kurzweil created the first electronic music keyboard to replicate the sound of a grand piano and many other instruments. If you’ve ever been to a rock concert, you’ve likely seen the name Kurzweil on the back of a synthesizer.

What Does it Mean to “Move to the Cloud”? This eBook Breaks Down the Myths

Again; many problems with AI & IoT all ties back to the infrastructure of things. Focus on fast tracking QC and an interim solution (pre-QC) such as a mix of Nvidia’s GPU, blockchain for financial transactions, etc. to improve the infrastructure and Net then investors will begin to pay more attention to AI, etc.

After more than 60 years since its conceptual inception — and after too many hype-generating moments — AI is yet again making its presence felt in mainstream media.

Following a recent WEF report, many perceive AI as a threat to our jobs, while others even go so far to assert that it poses a real threat to humanity itself.

What is clear for the time being is that there are many questions that still remain unanswered: Can we actually create conscious machines that have the ability to think and feel? What we do we mean by the word conscious in the first place? What is the accurate definition of intelligence? And what are the implications of combining the Internet of Things (IoT) with intelligence?

Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.

This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.

brainimage

“We are very excited about the approval of our protocol,” said Ira S. Pastor, CEO, Bioquark Inc. “With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies.”

Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.

While human beings lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, planarians, and certain fish, can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.

operation

Additionally, recent studies on complex brain regeneration in these organisms, have highlighted unique findings in relation to the storage of memories following destruction of the entire brain, which may have wide ranging implications for our understanding of consciousness and the stability of memory persistence.

“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer’s and Parkinson’s disease,” said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.

Over the years, clinical science has focused heavily on preventing such life and death transitions and made some initial progress with suspended animation technologies, such as therapeutic hypothermia. However, once humans transition through the brain death window, currently defined by the medical establishment as “irreversible”, they are technically no longer alive, despite the fact that human bodies can still circulate blood, digest food, excrete waste, balance hormones, grow, sexually mature, heal wounds, spike a fever, and gestate and deliver a baby. It is even acknowledged by thought leaders that recently brain dead humans still may have residual blood flow and electrical nests of activity in their brains, just not enough to allow for an integrated functioning of the organism as a whole.

coolbrain

“We look forward to working closely with Bioquark Inc. on this cutting edge clinical initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences.

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About Revita Life Sciences

Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.

X2 Biosystems awarded

They deserve it too.

X2 Biosystems has received the Society for Brain Mapping and Therapeutics (SBMT) 2016 Pioneer in Healthcare Technology Innovations Award for developing its next-generation head impact measurement sensor technology, the company said.

X2´s “X-Patch” wearable impact sensor has become widely deployed and tested head impact monitoring device, used in a continually expanding range of athletic activities from football (youth, high school, collegiate, pro) to hockey, soccer, lacrosse, rugby, Australian rules football, baseball, field hockey, wrestling, boxing, taekwondo, mixed martial arts, skiing and BMX cycling.

The X-Patch is also being actively evaluated for use in military training applications.

Hayfever drugs may shrink brain and raise dementia risk, warn scientists

Ugh — this is not good at all.

The study found lower metabolism and smaller brain sizes amoung the group of study participants taking anticholinergic drugs.

Medication with anticholinergic effects include certain over-the-counter antihistamines and nighttime cold medicines, and prescription drugs for sleep aid and many chronic diseases such as hypertension and cardiovascular disease.

Previous research found a link between between the anticholinergic drugs and cognitive impairment and increased risk of dementia. The problem is, those pills often come with a lengthy list of potential side effects.

Researchers can identify you by your brain waves with 100 percent accuracy

Could we see BMI technology used as part of our ID?

A team of researchers at Binghamton University, led by Assistant Professor of Psychology Sarah Laszlo and Assistant Professor of Electrical and Computer Engineering Zhanpeng Jin, recorded the brain activity of 50 people wearing an electroencephalogram headset while they looked at a series of 500 images designed specifically to elicit unique responses from person to person — e.g., a slice of pizza, a boat, Anne Hathaway, the word “conundrum.” They found that participants’ brains reacted differently to each image, enough that a computer system was able to identify each volunteer’s “brainprint” with 100 percent accuracy.

“When you take hundreds of these images, where every person is going to feel differently about each individual one, then you can be really accurate in identifying which person it was who looked at them just by their brain activity,” said Laszlo.

In their original study, titled “Brainprint,” published in 2015 in Neurocomputing, the research team was able to identify one person out of a group of 32 by that person’s responses, with only 97 percent accuracy, and that study only incorporated words, not images.

Common over-the-counter drugs can hurt your brain

Makes one assess their medicine cabinet especially those allergy meds, etc.

The new study is the first to examine the physical changes that serve as the catalyst for cognitive decline. Using brain imaging techniques, researchers at the Indiana University School of Medicine found (PDF) lower metabolism and reduced brain sizes among study participants taking anticholinergic drugs.

“These findings provide us with a much better understanding of how this class of drugs may act upon the brain in ways that might raise the risk of cognitive impairment and dementia,” said Shannon Risacher, an assistant professor of radiology and imaging sciences.

/* */